Pharmacogenomics in Solid Tumors: A Comprehensive Review of Genetic Variability and Its Clinical ImplicationsRodrigo Sánchez-Bayona, Milana Bergamino, Camila Catalán et al.|Cancers|2025Cited by 20
Efficacy outcomes of CDK4/6 inhibitors in combination with endocrine therapy treatment in hormone receptor-positive/HER2-negative advanced breast cancer according to PAM50 intrinsic subtype: Primary results of SOLTI-1801 CDK-PREDICT studyPablo Tolosa, Eva Ciruelos, Javier David Benítez Fuentes et al.|European Journal of Cancer|2025Cited by 10
HER2DX ERBB2 mRNA score in first-line advanced HER2-positive breast cancer treated with chemotherapy, trastuzumab, and pertuzumabRodrigo Sánchez-Bayona, Aleix Prat, Olga Martínez‐Sáez et al.|npj Breast Cancer|2025Cited by 6
Abstract P2-01-16: Pharmacogenomic variants and risk of adverse events in breast cancer patients treated with Trastuzumab-deruxtecan: results from the PROCURE projectRodrigo Sánchez-Bayona, Cristina Rodríguez‐Antona, Javier de Nicolás‐Hernández et al.|Clinical Cancer Research|2025Cited by 3
Efficacy analysis of CDK4/6 inhibitors (CDKi) + endocrine therapy (ET) treatment in hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer (aBC): Biomarker analysis including chemoendocrine score (CES) by CDKi type in SOLTI-1801_CDK-PREDICT study.Pablo Tolosa, Eva Ciruelos, Tomás Pascual et al.|Journal of Clinical Oncology|2023Cited by 0